Pregnancy-associated malaria

Last updated

Pregnancy-associated malaria (PAM) or placental malaria is a presentation of malaria in pregnancy which is life-threatening to both pregnant women and unborn fetuses. [1] PAM occurs when a pregnant woman contracts malaria, generally as a result of Plasmodium falciparum infection, and because she is pregnant, is at greater risk of associated complications such as placental malaria. [1] [2] [3] [4] Placental malaria interferes with the transmission of vital substances through the fetal placenta, which can result in stillbirths, miscarriages, and dangerously low birth weights. [5] [6] [7]

Contents

Prevention and treatment of malaria are essential components of prenatal care in tropical and subtropical geographic areas affected by malaria, and thus has received much international attention. [8] [9]

Signs and symptoms

Symptoms of malaria include malaise, headaches, fatigue, fever, muscle aches, abdominal pain, nausea and vomiting. More severe cases may present with seizures and even coma. [10] Women affected by PAM that have natural resistance to malaria [1] may experience normal, mild, or no symptoms of malaria and therefore often will not seek proper medical care. [11] [12]

Cause

Transmission

Transmission of malaria occurs when humans are bitten by mosquitos infected with the Plasmodium falciparum parasite, which enters the bloodstream as sporozoites.Over the next 7–30 days, the sporozites will convert to merozites in the liver and re-enter the bloodstream to infect erythrocytes.

Risk factors

Pregnant women and unborn fetuses are more susceptible to malaria infection due to the complications of pregnancy and the aggregation of erythrocytes around the placenta. [13] Infected erythrocytes express the VAR2CSA variant of P. falciparum erythrocyte membrane protein 1 (PfEMP1) which allows them to bind to chondroitin sulfate A (CSA) on placental proteoglycans and accumulate in the intervillous spaces of the placenta, blocking nutrient flow and causing inflammation. [1] [14]

Women are most susceptible to infection early in their first pregnancy due to absence of antibodies. [15] Those infected with human immunodeficiency virus (HIV) are also at greater risk of infection and associated symptoms due to the heightened parasite burden within the placenta during pregnancy. [16]

Mechanism

P. falciparum expresses proteins on the surface of parasite-infected erythrocytes (IE) helping them bind to an unusually low-sulfated form of chondroitin sulfate A (CSA) in the placental intervillous space. [17] [18] By this process, the parasite avoids being filtered through the spleen where it would be cleared from the bloodstream and killed. [19] [20] When selected in vitro for CSA-binding, the only upregulated gene expressed in the P. falciparum parasites was the var2csa gene. [21] Parasite clones - where the var2csa gene was disrupted - lost the ability to adhere to CSA by blocking the binding of IE. [18] [22] Its protein, VAR2CSA (Variant Surface antigen 2-CSA), belongs to the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family and contains six Duffy binding-like (DBL) domains. The regions that mediate binding to CSA have not been defined, but DBL2, DBL3, and DBL6 have shown the highest affinity for CSA binding when testing with recombinant single-domains. [18] [23]

A unique var gene (PFL0030c or var2csa) encodes this particular PfEMP1, which is differently regulated than other genes from the var family. [24] It is also only expressed as protein in pregnant women, even though the transcript is present in children, men and non-pregnant women. [25] It has a unique regulatory region, a uORF located upstream from the ORF that codes for the VAR2CSA protein. The expression of a protein named PTEF (after Plasmodium falciparum translation-enhancing factor) has been described to be necessary for the translation machinery to overcome the uORF and produce VAR2CSA protein, [26] but the mechanism behind it remains to be elucidated.

Maternalandfetaloutcomes

In general, women with PAM have a higher likelihood of premature births and infants with low birthweight. [27] In examination of possible malarial immunity, some studies have shown that the presence of "P. falciparum" antibodies (specifically CSA adhesion inhibitory antibodies or IgG antibodies) may decrease the likelihood of low birthweight in infants of women who have had pregnancy-associated malaria, but these findings do not specifically correlate to malarial immunity during pregnancy. [28] However, the relationship between many P. falciparum antibodies during pregnancy and maternal and birth outcomes remains variable.[ citation needed ]

Lower birthweight of infants born from mothers with PAM can be attributed to placental infection, as well as other complications such as anemia and malnutrition, since the malarial parasite can be passed vertically from mother to infant via infected red blood cells. [29] Children who are born with a birthweight below the mean are at risk for other health problems, including increased mortality risk. [29]

Anemia is a great concern as an adverse effect of pregnancy-associated malaria, since it can be life-threatening to the mother. [29] Its cause is often compounded by other factors, such as nutrition and genetics. Some studies have suggested that iron supplementation can help with maternal anemia, but more research on malaria-endemic regions is required to make a better recommendation for mothers with PAM. [30] [ needs update ]

One systematic review showed that children of women with PAM are also more likely to contract clinical malaria and P. falciparum parasitaemia, although the reasoning for this is uncertain. [31]

During epidemics, maternal death is one of the biggest complications of malaria in some areas. Furthermore, its cause is compounded with other malarial complications, such as anemia.

Prevention

Prevention of pregnancy-associated malaria can be done with the use of various antimalarial drugs given before or during pregnancy to susceptible populations. [32] Some of the antimalarial drugs used include Chloroquine, Mefloquine, and Sulfadoxine/pyrimethamine since they are safe for use during pregnancy. [32] [33] For regions of moderate or high malaria risk, preventative measures include insecticide-treated nets (ITNs) and intermittent preventative treatment in pregnancy (IPTp). [34] [35] ITNs act as two layers of protection. One is from the physical net and another from the chemical nature and effects of the insecticide. [36] Because IPTp plays a role in altering potential immune response displayed by infacts, the World Health Organization recommends starting IPTp as soon as possible during the second trimester. [34] These treatments are with doses of Sulfadoxine/pyrimethamine and are given at each antenatal visit, as long as the visits are one month apart. [37] One concern with the use of Sulfadoxine/pyrimethamine along with other antimalarial drugs is P. falciparum developing resistance. In areas that have higher rates of resistance to the antimalarial Sulfadoxine/pyrimethamine, two doses of the drug is effective in reducing maternal parasitemia in women that do not have HIV while more doses are needed to reduce maternal parasitemia in HIV-positive women. [38]

Management

Non-pharmacological treatment

Non-pharmacological treatment of PAM consists of utilizing the Artemisia annua plant as an herbal remedy. This reasoning is based on the fact that A. annua acts as the plant source for Artemisinin-based combination therapy (ACT), a commonly used pharmacological treatment of PAM. However, the WHO currently does not support the use of A. annua as there are no standardization guidelines for plant harvest and preparation. Also, its clinical safety and efficacy have not yet been proven. [39]

Pharmacological treatment

Treatment of PAM is highly dependant on the mother's current pregnancy stage (i.e. trimester) and the species responsible for the disease transmission.[ citation needed ]

For infection caused by P. falciparum, the WHO recommends a first trimester a treatment consisting of both Quinine and Clindamycin for a duration of 7 days. During the second and third trimester, the WHO recommendations of ACT, are the same as ones for non-pregnant individuals. [40] [41]

For infection caused by the other species, which include Plasmodium malariae , Plasmodium vivax , and Plasmodium ovale , the WHO recommends Chloroquine or Quinine during the first trimester. Quinine is used as an alternative if chloroquine-resistance is detected. During the second and third trimester, the WHO recommends either ACT or Chloroquine. If chloroquine-resistance is detected, ACT is the treatment of choice. [40] [41] The Centers for Disease Control and Prevention (CDC) has similar recommendations to the WHO. [42]

Epidemiology

Globally, an estimated 125 million or more pregnant women per year risk contracting PAM. [43] Pregnancy-related malaria causes around 100,000 infant deaths each year, largely due to low birth weight. [11]

Due to the nature of disease transmission (i.e. via mosquitoes) and life cycle of the parasite, malaria is prevalent in warm, humid climates, such as tropical and subtropical regions. [44] Consistent with previous years, the incidence of malaria in general is greatest in African regions, specifically sub-Saharan Africa, as defined by the World Health Organization - (WHO) - although there was a decline in numbers from 2010 to 2018. [29] Particularly, in 2018, the number of pregnancies in Central and West Africa with malarial infection reached around 35% of all pregnancies in those regions. [29] The regions that follow Africa in terms of malaria cases are Southeast Asia and the Mediterranean, although it is important to note that Africa has the largest number of cases by far; these regions comprise over 90% of the global incidences of malaria. [29]

In the realm of pregnancy, individual immunity and level of transmission by area play important roles in the malarial complications that manifest. [29] For example, areas with high levels of transmission are also associated with higher incidences of immunity. Therefore, infection by P. falciparum is usually associated with no symptoms in pregnant women. [29] However, it is not safe to conclude that the presence of P. falciparum is completely benign, as it has been associated with maternal anaemia. [29] Specifically, in these settings, women in their first pregnancy are at greatest risk of complications that arise from P. falciparum. [45] Similarly to P. falciparum, Plasmodium vivax (P. vivax), another malarial pathogen found primarily in Asia and South America, has also been associated with maternal anaemia and low birthweight. [29] [46] On the contrary, women who live in areas with lower transmission are at a very high risk of adverse malarial outcomes despite their number of pregnancies. [45]

Research directions

Each VAR2CSA domain has a potential affinity to CSA, but there are large areas not exposed to the immune system and appear to be buried in the quaternary structure. [20] [47] Data has indicated that these domains interact, forming a binding site that is specific for low-sulfated CSA found in the placenta. [20] [48] [49] The binding of antibodies to one of these domains would prevent adhesion of parasitic IE in the placenta.

Moreover, studies have shown that women acquire immunity to PAM through antibody recognition of the VAR2CSA domain, also known as VSAPAM, after exposure during their first pregnancy. By measuring circulating levels of IgG antibodies that presumably target VAR2SCA, the study demonstrated that subsequent pregnancies confer progressively greater protection to PAM. Thus, PfEMP1 proteins such as the VAR2CSA domain could prove attractive as potential candidates for vaccine targets. [50]

Additional genetic testing relating to pregnancy-associated malaria is currently being researched which involves looking at glucose-6-phosphate dehydrogenase - (G6PD) - an enzyme responsible for keeping red blood cells protected from being destroyed too soon by foods, medications, etc. [51] [52] The gene for this enzyme is found on the X chromosome which means that women, in particular, can have G6PD function that is normal, intermediate (which often shows up on lab tests as normal) and deficient. [51] This gene is important in determining if certain antimalarial drugs such as Primaquine and Tafenoquine can be used since these antimalarial drugs are more likely to cause red blood cell hemolysis (haemolysis) in women with a G6PD deficiency and worsen any anemia that results from malaria infection. [52] Although these drugs would most likely be used after delivery for treatment of pregnancy-associated malaria, this type of genetic testing can help avoid inducing anemia in women more prone to red blood cell breakdown.

A vaccine to prevent a type of pregnancy-associated malaria called PAMVAC is currently undergoing clinical trials. PAMVAC is based on a recombinant form of the VAR2CSA domain and has been shown to be well-tolerated when injected in malaria-naive volunteers while also successfully inducing the production of antibodies in opposition against VAR2CSA. [53] Although the vaccine was injected into participants who did not have malaria, the study provided insight into the vaccine's safety before administration into the target population – women with PAM. [53] [54]

A second vaccine candidate against pregnancy-associated malaria called PRIMVAC is also currently undergoing clinical trials in healthy adult women as a 3-dose course. This vaccine is based on the DBL1x-2x domain of VAR2CSA which is able to bind to CSA in the placenta. In preclinical studies, PRIMVAC injected into rats led to the production of antibodies against VAR2CSA on infected erythrocytes and also resulted in reduction of their binding to CSA. The vaccine was also shown to be well-tolerated in rats without any notable adverse reactions. [55]

Related Research Articles

<span class="mw-page-title-main">Malaria</span> Mosquito-borne infectious disease

Malaria is a mosquito-borne infectious disease that affects vertebrates and Anopheles mosquitoes. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin 10 to 15 days after being bitten by an infected Anopheles mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria. The mosquito vector is itself harmed by Plasmodium infections, causing reduced lifespan.

Antimalarial medications or simply antimalarials are a type of antiparasitic chemical agent, often naturally derived, that can be used to treat or to prevent malaria, in the latter case, most often aiming at two susceptible target groups, young children and pregnant women. As of 2018, modern treatments, including for severe malaria, continued to depend on therapies deriving historically from quinine and artesunate, both parenteral (injectable) drugs, expanding from there into the many classes of available modern drugs. Incidence and distribution of the disease is expected to remain high, globally, for many years to come; moreover, known antimalarial drugs have repeatedly been observed to elicit resistance in the malaria parasite—including for combination therapies featuring artemisinin, a drug of last resort, where resistance has now been observed in Southeast Asia. As such, the needs for new antimalarial agents and new strategies of treatment remain important priorities in tropical medicine. As well, despite very positive outcomes from many modern treatments, serious side effects can impact some individuals taking standard doses.

<i>Plasmodium falciparum</i> Protozoan species of malaria parasite

Plasmodium falciparum is a unicellular protozoan parasite of humans, and the deadliest species of Plasmodium that causes malaria in humans. The parasite is transmitted through the bite of a female Anopheles mosquito and causes the disease's most dangerous form, falciparum malaria. P. falciparum is therefore regarded as the deadliest parasite in humans. It is also associated with the development of blood cancer and is classified as a Group 2A (probable) carcinogen.

<span class="mw-page-title-main">Artemether</span> Chemical compound

Artemether is a medication used for the treatment of malaria. The injectable form is specifically used for severe malaria rather than quinine. In adults, it may not be as effective as artesunate. It is given by injection in a muscle. It is also available by mouth in combination with lumefantrine, known as artemether/lumefantrine.

<i>Plasmodium malariae</i> Species of single-celled organism

Plasmodium malariae is a parasitic protozoan that causes malaria in humans. It is one of several species of Plasmodium parasites that infect other organisms as pathogens, also including Plasmodium falciparum and Plasmodium vivax, responsible for most malarial infection. Found worldwide, it causes a so-called "benign malaria", not nearly as dangerous as that produced by P. falciparum or P. vivax. The signs include fevers that recur at approximately three-day intervals – a quartan fever or quartan malaria – longer than the two-day (tertian) intervals of the other malarial parasite.

<span class="mw-page-title-main">Merozoite surface protein</span>

Merozoitesurface proteins are both integral and peripheral membrane proteins found on the surface of a merozoite, an early life cycle stage of a protozoan. Merozoite surface proteins, or MSPs, are important in understanding malaria, a disease caused by protozoans of the genus Plasmodium. During the asexual blood stage of its life cycle, the malaria parasite enters red blood cells to replicate itself, causing the classic symptoms of malaria. These surface protein complexes are involved in many interactions of the parasite with red blood cells and are therefore an important topic of study for scientists aiming to combat malaria.

Antigenic variation or antigenic alteration refers to the mechanism by which an infectious agent such as a protozoan, bacterium or virus alters the proteins or carbohydrates on its surface and thus avoids a host immune response, making it one of the mechanisms of antigenic escape. It is related to phase variation. Antigenic variation not only enables the pathogen to avoid the immune response in its current host, but also allows re-infection of previously infected hosts. Immunity to re-infection is based on recognition of the antigens carried by the pathogen, which are "remembered" by the acquired immune response. If the pathogen's dominant antigen can be altered, the pathogen can then evade the host's acquired immune system. Antigenic variation can occur by altering a variety of surface molecules including proteins and carbohydrates. Antigenic variation can result from gene conversion, site-specific DNA inversions, hypermutation, or recombination of sequence cassettes. The result is that even a clonal population of pathogens expresses a heterogeneous phenotype. Many of the proteins known to show antigenic or phase variation are related to virulence.

Malaria prophylaxis is the preventive treatment of malaria. Several malaria vaccines are under development.

<span class="mw-page-title-main">Malaria antigen detection tests</span>

Malaria antigen detection tests are a group of commercially available rapid diagnostic tests of the rapid antigen test type that allow quick diagnosis of malaria by people who are not otherwise skilled in traditional laboratory techniques for diagnosing malaria or in situations where such equipment is not available. There are currently over 20 such tests commercially available. The first malaria antigen suitable as target for such a test was a soluble glycolytic enzyme Glutamate dehydrogenase. None of the rapid tests are currently as sensitive as a thick blood film, nor as cheap. A major drawback in the use of all current dipstick methods is that the result is essentially qualitative. In many endemic areas of tropical Africa, however, the quantitative assessment of parasitaemia is important, as a large percentage of the population will test positive in any qualitative assay.

Malaria vaccines are vaccines that prevent malaria, a mosquito-borne infectious disease which affected an estimated 249 million people globally in 85 malaria endemic countries and areas and caused 608,000 deaths in 2022. The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. As of April 2023, the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission. It requires at least three doses in infants by age 2, and a fourth dose extends the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30%.

<span class="mw-page-title-main">Hemozoin</span>

Haemozoin is a disposal product formed from the digestion of blood by some blood-feeding parasites. These hematophagous organisms such as malaria parasites, Rhodnius and Schistosoma digest haemoglobin and release high quantities of free heme, which is the non-protein component of haemoglobin. Heme is a prosthetic group consisting of an iron atom contained in the center of a heterocyclic porphyrin ring. Free heme is toxic to cells, so the parasites convert it into an insoluble crystalline form called hemozoin. In malaria parasites, hemozoin is often called malaria pigment.

Human genetic resistance to malaria refers to inherited changes in the DNA of humans which increase resistance to malaria and result in increased survival of individuals with those genetic changes. The existence of these genotypes is likely due to evolutionary pressure exerted by parasites of the genus Plasmodium which cause malaria. Since malaria infects red blood cells, these genetic changes are most common alterations to molecules essential for red blood cell function, such as hemoglobin or other cellular proteins or enzymes of red blood cells. These alterations generally protect red blood cells from invasion by Plasmodium parasites or replication of parasites within the red blood cell.

Russell J. Howard is an Australian-born executive, entrepreneur and scientist. He was a pioneer in the fields of molecular parasitology, especially malaria, and in leading the commercialisation of one of the most important methods used widely today in molecular biology today called “DNA shuffling" or "Molecular breeding", a form of "Directed evolution".

KAHRP is a protein expressed by Plasmodium falciparum infecting erythrocytes. KAHRP is a major component of knobs, feature found on Plasmodium falciparum infected erythrocytes.

In pregnancy, there is an increased susceptibility and/or severity of several infectious diseases.

Sanaria is a biotechnology company founded to develop whole-parasite vaccines protective against malaria. Sanaria is also developing monoclonal antibodies protective against malaria, vaccines against diarrheal diseases, immunotherapeutics for disease of the liver, and related products for us in malaria research. Sanaria's vaccines are based on the use of the sporozoite (SPZ) stage of the malaria parasite, Plasmodium, as an immunogen, and as a carrier for immunomodulatory molecules.

Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a family of proteins present on the membrane surface of red blood cells that are infected by the malarial parasite Plasmodium falciparum. PfEMP1 is synthesized during the parasite's blood stage inside the RBC, during which the clinical symptoms of falciparum malaria are manifested. Acting as both an antigen and adhesion protein, it is thought to play a key role in the high level of virulence associated with P. falciparum. It was discovered in 1984 when it was reported that infected RBCs had unusually large-sized cell membrane proteins, and these proteins had antibody-binding (antigenic) properties. An elusive protein, its chemical structure and molecular properties were revealed only after a decade, in 1995. It is now established that there is not one but a large family of PfEMP1 proteins, genetically regulated (encoded) by a group of about 60 genes called var. Each P. falciparum is able to switch on and off specific var genes to produce a functionally different protein, thereby evading the host's immune system. RBCs carrying PfEMP1 on their surface stick to endothelial cells, which facilitates further binding with uninfected RBCs, ultimately helping the parasite to both spread to other RBCs as well as bringing about the fatal symptoms of P. falciparum malaria.

<span class="mw-page-title-main">Quartan fever</span> Medical condition

Quartan fever is one of the four types of malaria which can be contracted by humans.

<i>Plasmodium</i> helical interspersed subtelomeric protein

The Plasmodium helical interspersed subtelomeric proteins (PHIST) or ring-infected erythrocyte surface antigens (RESA) are a family of protein domains found in the malaria-causing Plasmodium species. It was initially identified as a short four-helical conserved region in the single-domain export proteins, but the identification of this part associated with a DnaJ domain in P. falciparum RESA has led to its reclassification as the RESA N-terminal domain. This domain has been classified into three subfamilies, PHISTa, PHISTb, and PHISTc.

Reticulocyte binding protein homologs (RHs) are a superfamily of proteins found in Plasmodium responsible for cell invasion. Together with the family of erythrocyte binding-like proteins (EBLs) they make up the two families of invasion proteins universal to Plasmodium. The two families function cooperatively.

References

  1. 1 2 3 4 Srivastava A, Gangnard S, Round A, Dechavanne S, Juillerat A, Raynal B, et al. (March 2010). "Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA". Proceedings of the National Academy of Sciences of the United States of America. 107 (11): 4884–9. Bibcode:2010PNAS..107.4884S. doi: 10.1073/pnas.1000951107 . PMC   2841952 . PMID   20194779.
  2. ↑ "CDC-Malaria-Malaria Parasites". Centers for Disease Control and Prevention. 2019-01-28.
  3. ↑ Perlmann P, Troye-Blomberg M (2000). "Malaria blood-stage infection and its control by the immune system". Folia Biologica. 46 (6): 210–8. PMID   11140853.
  4. ↑ "Lives at Risk: Malaria in Pregnancy". WHO. Archived from the original on May 7, 2003. Retrieved March 30, 2011.
  5. ↑ Doolan DL, Dobaño C, Baird JK (January 2009). "Acquired immunity to malaria". Clinical Microbiology Reviews. 22 (1): 13–36, Table of Contents. doi:10.1128/CMR.00025-08. PMC   2620631 . PMID   19136431.
  6. ↑ Srivastava A, Gangnard S, Round A, Dechavanne S, Juillerat A, Raynal B, et al. (March 2010). "Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA". Proceedings of the National Academy of Sciences of the United States of America. 107 (11): 4884–9. Bibcode:2010PNAS..107.4884S. doi: 10.1073/pnas.1000951107 . PMC   2841952 . PMID   20194779.
  7. ↑ Matteelli A, Caligaris S, Castelli F, Carosi G (October 1997). "The placenta and malaria". Annals of Tropical Medicine and Parasitology. 91 (7): 803–10. doi:10.1080/00034989760563. PMID   9625937.
  8. ↑ Duffy PE, Fried M (2005). "Malaria in the Pregnant Woman". Malaria: Drugs, Disease and Post-genomic Biology. Current Topics in Microbiology and Immunology. Vol. 295. pp.  169–200. doi:10.1007/3-540-29088-5_7. ISBN   978-3-540-25363-1. PMID   16265891.
  9. ↑ "Roll Back Malaria: Malaria in Pregnancy". WHO. Archived from the original on 6 August 2006. Retrieved 18 April 2011.
  10. ↑ White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM (2014). "Malaria". The Lancet. 383 (9918): 723–735. doi:10.1016/s0140-6736(13)60024-0. PMID   23953767. S2CID   208794141.
  11. 1 2 Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD (February 2007). "Epidemiology and burden of malaria in pregnancy". The Lancet. Infectious Diseases. 7 (2): 93–104. doi:10.1016/S1473-3099(07)70021-X. PMID   17251080.
  12. ↑ "Burden of Malaria in Pregnancy in Latin America Not Known". Centers for Disease Control and Prevention. Retrieved April 14, 2011.
  13. ↑ Schantz-Dunn J, Nour NM (2009). "Malaria and pregnancy: a global health perspective". Reviews in Obstetrics & Gynecology. 2 (3): 186–92. PMC   2760896 . PMID   19826576.
  14. ↑ Zakama AK, Gaw SL (September 2019). "Malaria in Pregnancy: What the Obstetric Provider in Nonendemic Areas Needs to Know". Obstetrical & Gynecological Survey. 74 (9): 546–556. doi:10.1097/OGX.0000000000000704. PMC   7560991 . PMID   31830300.
  15. ↑ Gamain B, Smith JD, Viebig NK, Gysin J, Scherf A (March 2007). "Pregnancy-associated malaria: parasite binding, natural immunity and vaccine development". International Journal for Parasitology. 37 (3–4): 273–83. doi:10.1016/j.ijpara.2006.11.011. PMID   17224156.
  16. ↑ Kwenti TE (2018). "Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and treatment strategies". Research and Reports in Tropical Medicine. 9: 123–136. doi: 10.2147/rrtm.s154501 . PMC   6067790 . PMID   30100779.
  17. ↑ Fried M, Duffy PE (June 1996). "Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta". Science. 272 (5267). New York, N.Y.: 1502–4. Bibcode:1996Sci...272.1502F. doi:10.1126/science.272.5267.1502. PMID   8633247. S2CID   43040825.
  18. 1 2 3 Nielsen MA, Pinto VV, Resende M, Dahlbäck M, Ditlev SB, Theander TG, Salanti A (June 2009). "Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA". Infection and Immunity. 77 (6): 2482–7. doi:10.1128/IAI.00159-09. PMC   2687338 . PMID   19307213.
  19. ↑ David PH, Hommel M, Miller LH, Udeinya IJ, Oligino LD (August 1983). "Parasite sequestration in Plasmodium falciparum malaria: spleen and antibody modulation of cytoadherence of infected erythrocytes". Proceedings of the National Academy of Sciences of the United States of America. 80 (16): 5075–9. Bibcode:1983PNAS...80.5075D. doi: 10.1073/pnas.80.16.5075 . PMC   384191 . PMID   6348780.
  20. 1 2 3 Resende M, Ditlev SB, Nielsen MA, Bodevin S, Bruun S, Pinto VV, Clausen H, Turner L, Theander TG, Salanti A, Dahlbäck M (September 2009). "Chondroitin sulphate A (CSA)-binding of single recombinant Duffy-binding-like domains is not restricted to Plasmodium falciparum Erythrocyte Membrane Protein 1 expressed by CSA-binding parasites". International Journal for Parasitology. 39 (11): 1195–204. doi:10.1016/j.ijpara.2009.02.022. PMID   19324047.
  21. ↑ Salanti A, Staalsoe T, Lavstsen T, Jensen AT, Sowa MP, Arnot DE, Hviid L, Theander TG (July 2003). "Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria". Molecular Microbiology. 49 (1): 179–91. doi: 10.1046/j.1365-2958.2003.03570.x . PMID   12823820. S2CID   38384882.
  22. ↑ Viebig NK, Gamain B, Scheidig C, Lépolard C, Przyborski J, Lanzer M, Gysin J, Scherf A (August 2005). "A single member of the Plasmodium falciparum var multigene family determines cytoadhesion to the placental receptor chondroitin sulphate A". EMBO Reports. 6 (8): 775–81. doi:10.1038/sj.embor.7400466. PMC   1369142 . PMID   16025132.
  23. ↑ Gamain B, Trimnell AR, Scheidig C, Scherf A, Miller LH, Smith JD (March 2005). "Identification of multiple chondroitin sulfate A (CSA)-binding domains in the var2CSA gene transcribed in CSA-binding parasites". The Journal of Infectious Diseases. 191 (6): 1010–3. doi: 10.1086/428137 . PMID   15717280.
  24. ↑ Bancells C, Deitsch KW (November 2013). "A molecular switch in the efficiency of translation reinitiation controls expression of var2csa, a gene implicated in pregnancy-associated malaria". Molecular Microbiology. 90 (3): 472–88. doi:10.1111/mmi.12379. PMC   3938558 . PMID   23980802.
  25. ↑ Duffy MF, Caragounis A, Noviyanti R, Kyriacou HM, Choong EK, Boysen K, et al. (August 2006). "Transcribed var genes associated with placental malaria in Malawian women". Infection and Immunity. 74 (8): 4875–83. doi:10.1128/IAI.01978-05. PMC   1539630 . PMID   16861676.
  26. ↑ Chan S, Frasch A, Mandava CS, Ch'ng JH, Quintana MD, Vesterlund M, et al. (May 2017). "Regulation of PfEMP1-VAR2CSA translation by a Plasmodium translation-enhancing factor". Nature Microbiology. 2 (7): 17068. doi:10.1038/nmicrobiol.2017.68. PMID   28481333. S2CID   2276480.
  27. ↑ Thompson JM, Eick SM, Dailey C, Dale AP, Mehta M, Nair A, et al. (June 2020). "Relationship Between Pregnancy-Associated Malaria and Adverse Pregnancy Outcomes: a Systematic Review and Meta-Analysis". Journal of Tropical Pediatrics. 66 (3): 327–338. doi: 10.1093/tropej/fmz068 . PMID   31598714.
  28. ↑ Cutts JC, Agius PA, Powell R, Moore K, Draper B, Simpson JA, Fowkes FJ (January 2020). "Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review". BMC Medicine. 18 (1): 14. doi: 10.1186/s12916-019-1467-6 . PMC   6964062 . PMID   31941488.
  29. 1 2 3 4 5 6 7 8 9 10 World Malaria Report 2019. World Health Organization. 2019. ISBN   978-92-4-156572-1. OCLC   1156338614.
  30. ↑ Peña-Rosas JP, De-Regil LM, Garcia-Casal MN, Dowswell T (July 2015). "Daily oral iron supplementation during pregnancy". The Cochrane Database of Systematic Reviews. 2015 (7): CD004736. doi:10.1002/14651858.CD004736.pub5. PMC   4233117 . PMID   26198451.
  31. ↑ Park S, Nixon CE, Miller O, Choi NK, Kurtis JD, Friedman JF, Michelow IC (July 2020). "Impact of Malaria in Pregnancy on Risk of Malaria in Young Children: Systematic Review and Meta-Analyses". The Journal of Infectious Diseases. 222 (4): 538–550. doi:10.1093/infdis/jiaa139. PMC   7377293 . PMID   32219317.
  32. 1 2 Cot M, Deloron P (2003). "Malaria prevention strategies". British Medical Bulletin. 67 (1): 137–48. doi: 10.1093/bmb/ldg003 . PMID   14711760.
  33. ↑ CDC-Centers for Disease Control and Prevention (2019). "CDC - Malaria - Travelers - Choosing a Drug to Prevent Malaria". www.cdc.gov. Retrieved 2020-07-31.
  34. 1 2 Moya-Alvarez V, Abellana R, Cot M (July 2014). "Pregnancy-associated malaria and malaria in infants: an old problem with present consequences". Malaria Journal. 13 (1): 271. doi: 10.1186/1475-2875-13-271 . PMC   4113781 . PMID   25015559.
  35. ↑ Agboghoroma CO (2014). "Current management and prevention of malaria in pregnancy: a review". West African Journal of Medicine. 33 (2): 91–9. PMID   25236824.
  36. ↑ "Fact sheet about Malaria". www.who.int. Retrieved 2020-08-02.
  37. ↑ Gueneuc A, Deloron P, Bertin GI (January 2017). "Usefulness of a biomarker to identify placental dysfunction in the context of malaria". Malaria Journal. 16 (1): 11. doi: 10.1186/s12936-016-1664-0 . PMC   5209802 . PMID   28049536.
  38. ↑ ter Kuile FO, van Eijk AM, Filler SJ (June 2007). "Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review". JAMA. 297 (23): 2603–16. doi:10.1001/jama.297.23.2603. PMID   17579229.
  39. ↑ "The use of non-pharmaceutical forms of Artemisia". www.who.int. Archived from the original on June 7, 2020. Retrieved 2020-08-04.
  40. 1 2 World Health Organization (13 August 2015). Guidelines for the treatment of malaria (Third ed.). Geneva. ISBN   978-92-4-154912-7. OCLC   908628497.{{cite book}}: CS1 maint: location missing publisher (link)
  41. 1 2 Bauserman M, Conroy AL, North K, Patterson J, Bose C, Meshnick S (August 2019). "An overview of malaria in pregnancy". Seminars in Perinatology. 43 (5): 282–290. doi:10.1053/j.semperi.2019.03.018. hdl: 1805/22076 . PMC   7895297 . PMID   30979598.
  42. ↑ "Malaria - Diagnosis & Treatment (United States) - Treatment (U.S.) - Guidelines for Clinicians (Part 3)". www.cdc.gov. CDC-Centers for Disease Control and Prevention. 2019-03-27. Retrieved 2020-08-02.
  43. ↑ Worldwide Antimalarial Resistance Network (WWARN) (2016-01-28). "Malaria in Pregnancy Consortium". Worldwide Antimalarial Resistance Network. Retrieved 2020-08-04.
  44. ↑ "CDC - Malaria - About Malaria - Where Malaria Occurs". www.cdc.gov. CDC-Centers for Disease Control and Prevention. 2020. Retrieved 2020-07-31.
  45. 1 2 World Health Organization. "Malaria in pregnant women". WHO. Retrieved 2020-07-31.
  46. ↑ United Kingdom National Health Service (2018). "Malaria - Causes". nhs.uk. Retrieved 2020-07-31.
  47. ↑ Andersen P, Nielsen MA, Resende M, Rask TS, Dahlbäck M, Theander T, Lund O, Salanti A (February 2008). "Structural insight into epitopes in the pregnancy-associated malaria protein VAR2CSA". PLOS Pathogens. 4 (2): e42. doi: 10.1371/journal.ppat.0040042 . PMC   2242842 . PMID   18282103.
  48. ↑ Avril M, Gamain B, Lépolard C, Viaud N, Scherf A, Gysin J (2006). "Characterization of anti-var2CSA-PfEMP1 cytoadhesion inhibitory mouse monoclonal antibodies". Microbes and Infection. 8 (14–15): 2863–71. doi: 10.1016/j.micinf.2006.09.005 . PMID   17095277.
  49. ↑ Fernandez P, Viebig NK, Dechavanne S, Lépolard C, Gysin J, Scherf A, Gamain B (September 2008). "Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites". Malaria Journal. 7: 170. doi: 10.1186/1475-2875-7-170 . PMC   2543044 . PMID   18771584.
  50. ↑ Hviid L, Salanti A (2007). "VAR2CSA and protective immunity against pregnancy-associated Plasmodium falciparum malaria". Parasitology. 134 (Pt 13): 1871–6. doi:10.1017/S0031182007000121. PMID   17958922. S2CID   7706073.
  51. 1 2 "G6PD gene". Genetics Home Reference. Retrieved 2020-08-05.
  52. 1 2 Brummaier T, Gilder ME, Gornsawun G, Chu CS, Bancone G, Pimanpanarak M, et al. (January 2020). "Vivax malaria in pregnancy and lactation: a long way to health equity". Malaria Journal. 19 (1): 40. doi: 10.1186/s12936-020-3123-1 . PMC   6977346 . PMID   31969155.
  53. 1 2 Mordmüller B, Sulyok M, Egger-Adam D, Resende M, de Jongh WA, Jensen MH, et al. (October 2019). "First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria". Clinical Infectious Diseases. 69 (9): 1509–1516. doi:10.1093/cid/ciy1140. PMC   6792113 . PMID   30629148.
  54. ↑ GEN (2019-01-10). "Pregnancy-Associated Malaria Vaccine Passes First Human Trial". GEN - Genetic Engineering and Biotechnology News. Retrieved 2020-08-02.
  55. ↑ Chêne A, Gangnard S, Guadall A, Ginisty H, Leroy O, Havelange N, et al. (April 2019). "Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVAC". eBioMedicine. 42: 145–156. doi:10.1016/j.ebiom.2019.03.010. PMC   6491931 . PMID   30885725.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.